This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ertel, I. J. Articles by Sather, H. Search for Related Content PubMed PubMed Citation Articles by Ertel, I. J. Articles by Sather, H.

Effective Dose of L-Asparaginase for Induction of Remission in Previously Treated Children with Acute Lymphocytic Leukemia: A Report from Childrens Cancer Study Group¹

University of Michigan, Ann Arbor, Michigan 48109 [I. J. E.]; University of Minnesota Hospital, Minneapolis, Minnesota 55455 [M. E. N.]; University of Southern California, Los Angeles, California 90033 [D. H.]; and Childrens Cancer Study Group, Operations Office, Los Angeles, California 90031 [J. W., H. N. S.]

L-Asparaginase, in the dose of 6000 IU/sq m three times weekly, was demonstrated to be an effective agent in reinduction of remissions in childhood leukemia.

Four hundred thirteen children with acute lymphocytic leukemia were treated with L-asparaginase. Doses i.m. ranged from 300 to 12,000 IU/sq m. None of the patients had received prior asparaginase therapy. 6-Mercaptopurine was given p.o. concurrently. All of the patients had experienced several previous relapses, and their disease was not responsive to 6-mercaptopurine. L-Asparaginase was found to be effective in reinducing remissions at the following rates: 9.5% for 300 IU/sq m; 35.1% for 3,000 IU/sq m; 53.5% for 6,000 IU/sq m; and 62.5% for 12,000 IU/sq m. The drug was given three times weekly for four weeks. Hypersensitivity reactions occurred in 6.5% of patients.

¹ Childrens Cancer Study Group investigators, institutions, and grant numbers are given in "Appendix." Address requests for reprints to Childrens Cancer Study Group Operations Office, 1721 Griffin Avenue, Los Angeles, Calif. 90031.

Received 2/ 8/79. Accepted 6/26/79.

This article has been cited by other articles:

				P. A. Dinndorf, J. Gootenberg, M. H. Cohen, P. Keegan, and R. Pazdur FDA Drug Approval Summary: Pegaspargase (Oncaspar(R)) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL) Oncologist, August 1, 2007; 12(8): 991 - 998. [Abstract] [Full Text] [PDF]

				D. Douer, H. Yampolsky, L. J. Cohen, K. Watkins, A. M. Levine, A. P. Periclou, and V. I. Avramis Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia Blood, April 1, 2007; 109(7): 2744 - 2750. [Abstract] [Full Text] [PDF]

				M. H. Woo, L. J. Hak, M. C. Storm, J. T. Sandlund, R. C. Ribeiro, G. K. Rivera, J. E. Rubnitz, P. L. Harrison, B. Wang, W. E. Evans, et al. Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., April 7, 2000; 18(7): 1525 - 1532. [Abstract] [Full Text] [PDF]

				M. H. Woo, L. J. Hak, M. C. Storm, A. J. Gajjar, J. T. Sandlund, P. L. Harrison, B. Wang, C.-H. Pui, and M. V. Relling Cerebrospinal Fluid Asparagine Concentrations After Escherichia coli Asparaginase in Children With Acute Lymphoblastic Leukemia J. Clin. Oncol., May 1, 1999; 17(5): 1568 - 1568. [Abstract] [Full Text] [PDF]

				Y. Inada, A. Matsuswma, Y. Kodera, and H. Nishimura Review : Polyethylene Glycol(PEG)-Protein Conjugates: Application to Biomedical and Biotechnological Processes Journal of Bioactive and Compatible Polymers, January 1, 1990; 5(3): 343 - 364. [PDF]